1. Home
  2. Analysis
  3. Methimazole
  4. Jakafi

Methimazole and Jakafi drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Methimazole (methimazole) and Jakafi (ruxolitinib phosphate). Common drug interactions include abdominal pain among females.

The phase IV clinical study analyzes what interactions people have when they take Methimazole and Jakafi. It is created by eHealthMe based on reports of 52 people who take the same drugs from the FDA, and is updated regularly.

What is Methimazole?

Methimazole has active ingredients of methimazole. It is often used in hyperthyroidism. eHealthMe is studying from 8,016 Methimazole users. Check the latest studies of Methimazole.

What is Jakafi?

Jakafi has active ingredients of ruxolitinib phosphate. It is often used in primary myelofibrosis. eHealthMe is studying from 56,530 Jakafi users. Check the latest studies of Jakafi.

On Jul, 19, 2026

52 people who take Methimazole and Jakafi together, and have interactions are studied.

Methimazole and Jakafi drug interactions.

What are the common drug interactions of Methimazole and Jakafi, by gender? *:

female:

  1. Abdominal pain
  2. Asthenia (weakness)
  3. Deficiency anaemia
  4. Diarrhoea
  5. Dizziness
  6. Dyspnoea at rest (difficult or laboured breathing during rest)
  7. Dyspnoea exertional (breathlessness or shortness of breath)
  8. Eating disorder
  9. Haemorrhage (bleeding)
  10. Iron deficiency

male:

n/a

What are the common drug interactions of Methimazole and Jakafi, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

  1. Abdominal distension
  2. Abdominal pain
  3. Contusion (a type of hematoma of tissue in which capillaries)
  4. Deficiency anaemia
  5. Diarrhoea
  6. Dizziness
  7. Dyspnoea at rest (difficult or laboured breathing during rest)
  8. Dyspnoea exertional (breathlessness or shortness of breath)
  9. Eating disorder
  10. Fatigue (feeling of tiredness)

What are the existing conditions these people have? *

  1. Polycythaemia Vera (blood disorder in which the bone marrow makes too many red blood cells): 28 people, 53.85%
  2. Thyroid Diseases: 3 people, 5.77%
  3. Graft Versus Host Disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body): 3 people, 5.77%
  4. Fibromyalgia (a long-term condition which causes pain all over the body): 3 people, 5.77%
  5. Depression: 3 people, 5.77%
  6. Dementia Alzheimer's Type (loss of mental ability with alzheimer's symptom): 3 people, 5.77%
  7. Breast Cancer: 3 people, 5.77%
  8. Blood Pressure Abnormal: 3 people, 5.77%

* Approximation only. Some reports may have incomplete information.

Do you take Methimazole and Jakafi?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Methimazole and Jakafi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Methimazole:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Jakafi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Methimazole and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Jakafi and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on methimazole and ruxolitinib phosphate (the active ingredients of Methimazole and Jakafi, respectively), and Methimazole and Jakafi (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.